ATC Group: R03CA02 Ephedrine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R03CA02 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R03 Drugs for obstructive airway diseases
3 R03C Adrenergics for systemic use
4 R03CA Alpha- and beta-adrenoreceptor agonists
5 R03CA02 Ephedrine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 50 mg

Active ingredients in R03CA02

Active Ingredient Description
Ephedrine

Ephedrine is a sympathomimetic amine acting directly on the alpha and beta receptors and indirectly by increasing the release of noradrenaline by the sympathetic nerve endings. As with any sympathomimetic agent, ephedrine stimulates the central nervous system, the cardiovascular system, the respiratory system, and the sphincters of the digestive and urinary systems.

Related product monographs

Title Information Source Document Type  
EPHEDRINE 1.0% Nasal drops Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
EPHEDRINE HYDROCHLORIDE Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
EPHEDRINE HYDROCHLORIDE Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.